3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
108
Phase 1
100
Phase 1/2
81
Phase 3
22
Phase EARLY_PHASE1
6
Phase 2/3
5
Phase NA
3
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Head & Neck
2
Tumor-Agnostic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Imiquimod
15
Aminolevulinic Acid
8
Fluorouracil
6
Diclofenac
6
3-ingenyl angelate
6
Nivolumab
5
Cryotherapy
5
tirbanibulin
4
methyl 5-aminolevulinate
4
Sirolimus
4
denileukin diftitox
3
aldesleukin
3
Photochemotherapy
3
Ipilimumab
3
Blood Specimen Collection
3
relatlimab
2
Vemurafenib
2
Tacrolimus
2
Prednisone
2
Ointments
2
Methotrexate
2
Immune Checkpoint Inhibitors
2
HhAntag691
2
Gels
2
Cyclosporine
2
Cryosurgery
2
trametinib
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
technetium Tc 99m nanocolloid
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
pembrolizumab
×
Dermatologic
×
Clear all
NCT03715205
2025-08-29
Keynote-593
Merck Sharp & Dohme LLC
Phase 4
Completed
150 enrolled
14 charts